132 related articles for article (PubMed ID: 9134974)
1. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats.
Sethy VH; Wu H; Oostveen JA; Hall ED
Brain Res; 1997 Apr; 754(1-2):181-6. PubMed ID: 9134974
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats.
Sethy VH; Wu H; Oostveen JA; Hall ED
Neurosci Lett; 1997 May; 228(1):45-9. PubMed ID: 9197284
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of the pyrrolopyrimidine U-104067F in 3-acetylpyridine-treated rats.
Sethy VH; Wu H; Oostveen JA; Hall ED
Exp Neurol; 1996 Jul; 140(1):79-83. PubMed ID: 8682182
[TBL] [Abstract][Full Text] [Related]
4. Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2014 Apr; 262():1-7. PubMed ID: 24361908
[TBL] [Abstract][Full Text] [Related]
5. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Vu TQ; Ling ZD; Ma SY; Robie HC; Tong CW; Chen EY; Lipton JW; Carvey PM
J Neural Transm (Vienna); 2000; 107(2):159-76. PubMed ID: 10847557
[TBL] [Abstract][Full Text] [Related]
6. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].
Danzeisen R; Schwalenstoecker B; Gillardon F; Buerger E; Krzykalla V; Klinder K; Schild L; Hengerer B; Ludolph AC; Dorner-Ciossek C; Kussmaul L
J Pharmacol Exp Ther; 2006 Jan; 316(1):189-99. PubMed ID: 16188953
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Prikhojan A; Brannan T; Yahr MD
J Neural Transm (Vienna); 2000; 107(10):1159-64. PubMed ID: 11129105
[TBL] [Abstract][Full Text] [Related]
9. Correlations between cerebellar cyclic GMP and motor effects induced by deltamethrin: independence of olivo-cerebellar tract.
Brodie ME
Neurotoxicology; 1983; 4(4):1-11. PubMed ID: 6322058
[TBL] [Abstract][Full Text] [Related]
10. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
Le WD; Jankovic J
Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
[TBL] [Abstract][Full Text] [Related]
11. Activity-induced elevation of cerebellar cyclic GMP occurs in the absence of climbing fiber pathways.
McCaslin PP; Morgan WW
Brain Res; 1987 Jun; 414(2):381-4. PubMed ID: 3040168
[TBL] [Abstract][Full Text] [Related]
12. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
J Neural Transm (Vienna); 1997; 104(4-5):525-33. PubMed ID: 9295183
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
Carvey PM; Pieri S; Ling ZD
J Neural Transm (Vienna); 1997; 104(2-3):209-28. PubMed ID: 9203083
[TBL] [Abstract][Full Text] [Related]
15. [Morphologic changes in the rat inferior olive after its neurotoxic destruction with different doses of 2-acetylpyridine].
Melik-Musian AB; Oganesian EA; Fanardzhian VV
Morfologiia; 1999; 116(4):15-8. PubMed ID: 10486802
[TBL] [Abstract][Full Text] [Related]
16. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
Presgraves SP; Borwege S; Millan MJ; Joyce JN
Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
[TBL] [Abstract][Full Text] [Related]
17. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of pramipexole and sertraline in the forced swimming test.
Maj J; Rogóz Z
Pol J Pharmacol; 1999; 51(6):471-5. PubMed ID: 10817524
[TBL] [Abstract][Full Text] [Related]
19. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study.
Ferger B; Teismann P; Mierau J
Brain Res; 2000 Nov; 883(2):216-23. PubMed ID: 11074050
[TBL] [Abstract][Full Text] [Related]
20. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
